| 2022 | A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Anaplastic thyroid carcinoma arising from a calcified thyroid mass
| JOURNAL OF CLINICAL ONCOLOGY |
| 2000 | Angiocentric lymphoma of the head and neck: Patterns of systemic failure after radiation treatment | Journal of Clinical Oncology |
| 2021 | Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients | JOURNAL OF CLINICAL ONCOLOGY |
| 2011 | Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2011 | Discordance in perceived needs between patients and physicians in oncology practice: a nationwide survey in Korea. | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC)
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Early experience of combining immune checkpoint inhibitor and radiotherapy in heavily pretreated hepatobiliary cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
| JOURNAL OF CLINICAL ONCOLOGY |
| 2005 | Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2012 | Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group | JOURNAL OF CLINICAL ONCOLOGY |
| 2013 | Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2010 | Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors | JOURNAL OF CLINICAL ONCOLOGY |
| 2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials | JOURNAL OF CLINICAL ONCOLOGY |
| 2010 | Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2014 | Incorporation of pazopanib in maintenance therapy of ovarian cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2007 | Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Job loss and re-employment of cancer patients in Korean employees: a nationwide retrospective cohort study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2014 | Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Liver-directed concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombus | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2014 | Long-Term Results of Laparoscopic Gastrectomy for Gastric Cancer: A Large-Scale Case-Control and Case-Matched Korean Multicenter Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy | JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
| JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. | JOURNAL OF CLINICAL ONCOLOGY |
